Company Overview
Financials & Stats
Revenue
$50B
Recent News & Media
Third Circuit: Royalties not always tied to patent expiration
- Sep 4, 2024
- bioworld.com
Dyax backs albumin
- Mar 21, 2018
- nature.com
Shire’s $6.5 Billion Dyax Bet Pays Off as Lanadelumab Wows in Phase III Study
- May 18, 2017
- biospace.com
Pathways to Entrepreneurship: Ivana Magovcevic-Liebisch, JD, PhD
- Apr 26, 2016
- otd.harvard.edu
Irish Drug Maker Shire Agrees to Buy Dyax in Deal Worth Up to $6.5 Billion (Published 2015)
- Nov 2, 2015
- nytimes.com
Shire to buy US biotech group Dyax for $5.9bn
- Nov 2, 2015
- ft.com
Who is Dyax
Dyax was a biotechnology company headquartered in Burlington, Massachusetts. The company employed 62 people and generated approximately $50 million in annual revenue. Dyax focused on the development and commercialization of novel therapies for rare and serious diseases. Their product portfolio included treatments for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. Dyax was known for its innovative approach to drug development, utilizing a proprietary platform technology to create targeted therapies. Their commitment to patient care and scientific excellence positioned them as a leader in the field of HAE treatment. For further information, please visit Shire's LinkedIn page at www.linkedin.com/company/shire or www.shire.com.
Companies Similar to Dyax
Analyze industry trends and opportunities by examining competitors and companies comparable to Dyax, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 50M | Cambridge, MA | |||
| 50M | 24 | Cambridge, MA | ||
| 50M | 68 | Cambridge, MA | 2000 | |
| 50M | 7 | Boston, MA | 2006 | |
| 50M | 225 | Boston, MA | 2002 |